Immunome, Inc. (IMNM)
18.71
+0.80
(+4.50%)
USD |
NASDAQ |
Nov 06, 16:00
19.49
+0.78
(+4.17%)
After-Hours: 20:00
Immunome Research and Development Expense (Annual) : 174.33M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 174.33M |
| December 31, 2024 | 127.44M |
| December 31, 2023 | 103.16M |
| December 31, 2022 | 22.64M |
| Date | Value |
|---|---|
| December 31, 2021 | 13.36M |
| December 31, 2020 | 6.731M |
| December 31, 2019 | 8.208M |
| December 31, 2018 | 6.356M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Revolution Medicines, Inc. | 978.68M |
| Erasca, Inc. | 92.85M |
| Oncolytics Biotech, Inc. | 13.31M |
| Sangamo Therapeutics, Inc. | 112.67M |